BlackRock Advisors’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

BlackRock Advisors’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$124K	Buy	8,287 +639	+8%	+$8.97K	﹤0.01%	2943
2016 Q3	$96K	Hold	7,648	–	–	﹤0.01%	3041
2016 Q2	$69K	Sell	7,648 -5,381	-41%	-$52.7K	﹤0.01%	3130
2016 Q1	$129K	Buy	13,029 +7,164	+122%	+$73.5K	﹤0.01%	2793
2015 Q4	$67K	Sell	5,865 -3,031	-34%	-$37.5K	﹤0.01%	3097
2015 Q3	$120K	Sell	8,896 -1,216	-12%	-$16.5K	﹤0.01%	3009
2015 Q2	$140K	Buy	10,112 +1,794	+22%	+$24.3K	﹤0.01%	3018
2015 Q1	$117K	Buy	8,318 +3,216	+63%	+$43.8K	﹤0.01%	2968
2014 Q4	$69K	Sell	5,102 -368	-7%	-$5.03K	﹤0.01%	3200
2014 Q3	$84K	Sell	5,470 -146,525	-96%	-$2.24M	﹤0.01%	3098
2014 Q2	$2.56M	Sell	151,995 -152,513	-50%	-$2.75M	﹤0.01%	1112
2014 Q1	$6.11M	Sell	304,508 -6,450	-2%	-$140K	0.01%	925
2013 Q4	$6.03M	Buy	+310,958	New	+$5.5M	0.01%	948

Other funds holding OXFD

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

BlackRock Advisors's OXFD Position: Q4 2016 in Review

BlackRock Advisors increased its Oxford Immunotec Global PLC Ordinary Shares (OXFD) stake by 8.4% in Q4 2016, buying an estimated $8.97K and bringing the position to 8,287 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #2943.

BlackRock Advisors first reported a position in OXFD in Q4 2013 and has held it in 13 quarters since. The position peaked at $6.11M in Q1 2014. 73 funds tracked by Wall St. Rank hold OXFD as of Q4 2016.

BlackRock Advisors held 8,287 shares of Oxford Immunotec Global PLC Ordinary Shares worth $124K as of Q4 2016.
BlackRock Advisors bought 639 Oxford Immunotec Global PLC Ordinary Shares shares in Q4 2016, an estimated $8.97K.
Oxford Immunotec Global PLC Ordinary Shares made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2943 holding.
BlackRock Advisors first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and has held it in 13 quarters since.
BlackRock Advisors's Oxford Immunotec Global PLC Ordinary Shares position peaked at $6.11M in Q1 2014.
73 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.